Since its founding in 1990, the DDRCC at UChicago has stood at the forefront of medical research. Today, we have a research base of over 70 members. Our four cores are each led by top investigators, committed not only to the highest level of innovation in their own fields, but to sharing their research with colleagues in other cores. This integrated, multidisciplinary approach is evident in that more than 50% of publications made possible through the C-IID each year are the result of collaborations.
- To foster and strengthen multi-disciplinary and collaborative DD research to advance the science and translation of discovery in DD.
- To develop and implement programs for training and establishment of young investigators in DD-related research through a robust Enrichment program and P&F program.
- To attract new investigators to DD-related research by developing cross-cutting initiatives and fostering interaction and collaborations with C-IID investigators.
- To promote robust translational research in DD through development of programmatic initiatives and infrastructure, both intramural and extramural.
- To enhance the collaborative environment and enable cutting edge research by anticipating and leveraging new technologies and expertise to develop cost-effective, high quality core services.
We strive to provide our state-of-the-art core facilities and services through the most cost-efficient means possible. Our robust research base has an annual direct cost of $12 million. More than 40% of this funding is provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Pilot and Feasibility Funding Program
Each year our P & F Program funds innovative pilot programs in areas relevant to the DDRCC’s overall mission. Applications are typically due in September. Click here to see latest announcement.
Pilot and Feasibility awards are offered for the purposes of:
- Attracting junior faculty members, including senior research fellows, into the mission areas of the DDRCC. This is the principal target group and is intended ideally for candidates without current NIH or other significant extramural support to initiate research into digestive diseases.
- Allowing more established faculty members, who are not currently engaged in gastrointestinal research, to extend their investigations into the mission areas of the DDRCC.
- Permitting any faculty member to test a novel hypothesis related to any of the mission areas of the DDRCC, which might not yet meet NIH requirements of feasibility for R01 funding.
Applications which emphasize DDRCC core use and which will strengthen collaborative interactions among scientists within the digestive disease research community are particularly encouraged. It is strongly anticipated that the results of these pilot projects will eventually permit investigators to compete successfully for extramural research support in IBD and related areas of gastrointestinal research.
Broad aspects of basic and translational/clinical research related to enteric microbiology, inflammation, and immunology of the digestive tract and pathogenesis, genetics, pathophysiology, and bench-to-bedside aspects of inflammatory bowel disease, celiac disease or food allergy will be given higher priority. In addition, proposals focused on the examination of growth and differentiation, cancer biology, intestinal epithelial biology and pathobiology of the gastrointestinal tract (including the luminal GI tract, liver, pancreas, biliary system, etc.), as well as basic or clinical research in the areas of nutrition and digestive diseases are appropriate topics for Pilot & Feasibility studies. Please feel free to ask for guidance if you are unsure about the suitability of your topic or project.
See the following for examples of past funded proposals and the range of research activities supported through this mechanism.
- Fotini Gounari, Ph.D. (Immunology): T-cell specific activation of β-catenin induces IL-17 mediated inflammatory bowel disease and dysplasia
- Eugene A Choi M.D. (Department of Surgery): The Role of Raf-1 Kinase Inhibitory Protein (RKIP) in Colorectal Cancer Metastasis
Period and Amount of Funding:
Funds for Pilot & Feasibility projects are available for an initial period of one year and are limited to a maximum of $37,500 in direct costs. In general, funds have been allocated in the range of $30,000 to $37,500, although in exceptional circumstances, awards have been made up to the maximum allowable amount. Successful candidates are required to provide a progress report 6 months into the fiscal year for continuation of funding. Outcome of progress during the first year will determine if applicants will be invited to reapply for a second year of funding.
Congratulations to this year's award recipients: Bryan Dickinson, A. Murat Eren, Daria Esterhazy, Steve Kron, and Yeva Shan.
Questions? Contact P&F Program Director Dr. Eugene Chang.
Please acknowledge support from the DDRCC (NIDDK P30DK42086) in your publications and presentations.